The groundbreaking success of Viagra undeniably revolutionized the pharmaceutical landscape, but placing funds in companies heavily reliant on off-patent versions presents a challenging picture. While early profits were significant, the expiration of patents and the emergence of less expensive alternatives have eroded sales. Thus, a thorough analys